Skip to main content
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 4 - June 2018
  3. Intestinal microbiota modulates tumour response in cancer patients
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 4 - June 2018
  3. Intestinal microbiota modulates tumour response in cancer patients
Gastroenterology

Intestinal microbiota modulates tumour response in cancer patients

Cancer

Press review

By Pr. Ener Cagri Dinleyici
Professor in Pediatrics, Eskisehir Osmangazi University Faculty of Medicine; Department of Pediatrics, Eskisehir, Turkey

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

Sections

Photo : Intestinal microbiota modulates tumour response in cancer patients

About this article

Created 26 August 2021
Updated 24 September 2021

On February 4, 2018, World Cancer Day, the World Health Organization (WHO) stated on their website “Nearly every family in the world is touched by cancer, which is now responsible for almost one in six deaths globally. On World Cancer Day (February 4), the WHO highlights that cancer no longer needs to be a death sentence, as the capacity exists to reduce its burden and improve the survival and quality of life of people living with the disease” [1].

Over the last 10 years, tremendous advances have been made for cancer patients using new treatment strategies, including immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated antigen (CTLA-4) and programmed death 1 (PD-1) protein. However, therapeutic responses to these new treatment modalities are often heterogeneous, and some non-responder patients have been reported. The intestinal microbiome has been suggested to be an important host factor for non-responder patients, along with tumour genomics. Previous studies on microbiota and cancer have mainly focused on alterations in the intestinal microbiota of cancer patients (oncobiome) or microbiota precursors in order to define early-stage cancers, mainly colorectal cancers. However, promising new results regarding the influence of intestinal microbiota on anti-tumour immune responses have emerged. Two new studies were published in the first issue of Science this year.

• Gopalakrishnan et al. [2] evaluated the intestinal and oral microbiome in 112 patients with malignant melanoma, receiving anti-PD-1 immunotherapy, and compared baseline microbiota composition between cancer responders and non-responders. They revealed significant differences in the diversity and composition of intestinal microbiota between responders and non-responders. Significantly higher alpha diversity and relative abundance of Ruminococcaceae/Faecalibacterium was observed in responders, and this favourable intestinal microbiota composition has been suggested to enhance systemic and anti-tumour immunity among patients with melanoma. Patients with a low diversity and relatively high abundance of Bacteroidales (unfavourable intestinal microbiome) have impaired anti-tumour immune responses.

• Matson et al. [3] also evaluated the composition of baseline intestinal microbiota in patients with metastatic melanoma before receiving anti-PD-L1 therapy. Among the responders to treatment, Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium have been shown to be predominant members of the microbiota. These authors suggest that the commensal microbiome may exhibit a mechanistic impact on anti-tumour immunity in patients with metastatic melanoma. In the light of the results from these two previous clinical studies, it is thought that baseline intestinal microbiota may play a critical role in mediating the immune- stimulant response in melanoma patients receiving immunotherapy, such as anti-PD-L1 therapy. Further prospective studies are needed to reveal the precise interactions between the microbiome and cancer, not only in melanoma patients, but in terms of potential relevance for all types of cancer and the different treatment strategies.

Sources

1 World Cancer Day 2018. http://www.who.int/cancer/world-cancer- day/2018/en/

2 Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359: 97-103.

3 Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018; 359: 104-8.

4 Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother 2018: 1-14.

Tags
Gastroenterology Oncology Immunity

en_view en_sources

    Focus
    Microbiota 4 - June 2018
    • Overview
      • Targeting the gut microbiota to combat allergies
    • Commented articles
      • The role of Fusobacterium in colorectal cancer
      • Adaptation of commensal Escherichia coli in the intestinal tract of young children with cystic fibrosis
    • Congress review
      • 2017 UEG WEEK
      • Focus on the 2018 GMFH
    • Press review
      • Intestinal microbiota modulates tumour response in cancer patients
      • Maternal obesity during pregnancy and delivery mode
    Created 26 August 2021
    Updated 24 September 2021

    About this article

    To know more about this topic.

    Main topic

    Cancer

    Content type

    Press review
    Focus on the 2018 GMFH
    Maternal obesity during pregnancy and delivery mode
    Focus

    Microbiota 4 - June 2018

    Overview

    Targeting the gut microbiota to combat allergies

    Commented articles

    The role of Fusobacterium in colorectal cancer Adaptation of commensal Escherichia coli in the intestinal tract of young children with cystic fibrosis

    Congress review

    2017 UEG WEEK Focus on the 2018 GMFH

    Press review

    Intestinal microbiota modulates tumour response in cancer patients Maternal obesity during pregnancy and delivery mode
    Gastroenterology
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    en_redirection

    en_you_are_about_to_leave

    • en_be_redirected
    • en_stay_on_biocodex

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo